{"id":130496,"date":"2026-06-25T11:33:47","date_gmt":"2026-06-25T06:03:47","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=130496"},"modified":"2026-06-25T11:33:49","modified_gmt":"2026-06-25T06:03:49","slug":"dr-reddys-laboratories-q1-results-fy27","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/","title":{"rendered":"Dr Reddys Laboratories Q1 Results FY27: Uniresearch Predictions, Analyst Views and Key Watchpoints"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Dr Reddys Laboratories Q1 Results FY27: Uniresearch projects Revenue Rs 9,121 Cr | PAT Rs 1,449 Cr (39-analyst consensus). Q4 FY26: Rev Rs 7,546 Cr | PAT Rs 221 Cr.<\/em><\/p>\n<p>The <a href=\"https:\/\/univest.in\/user\/stocks\/drreddy\/dr-reddy's-laboratories-ltd-share-price-today\">Dr Reddys Laboratories<\/a> Q1 Results FY27 outlook is anchored on Q4 FY26 verified actuals and Uniresearch analysis applying the 39-analyst FY27 consensus to Q1 FY26 verified actuals. Uniresearch projects Revenue Rs 9,121 Cr (+6.4% YoY) and PAT Rs 1,449 Cr (+2.8% YoY). Prepared by Ankit Jaiswal.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=dr-reddys-laboratories-q1-results-f\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#Dr_Reddys_Laboratories_Q1_Results_FY27_%E2%80%93_Uniresearch_Prediction\" title=\"Dr Reddys Laboratories Q1 Results FY27 &#8211; Uniresearch Prediction\">Dr Reddys Laboratories Q1 Results FY27 &#8211; Uniresearch Prediction<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#Dr_Reddys_Laboratories_Q4_FY26_Key_Metrics_%E2%80%93_Baseline_for_Dr_Reddys_Laboratories_Q1_Results_FY27\" title=\"Dr Reddys Laboratories Q4 FY26 Key Metrics &#8211; Baseline for Dr Reddys Laboratories Q1 Results FY27\">Dr Reddys Laboratories Q4 FY26 Key Metrics &#8211; Baseline for Dr Reddys Laboratories Q1 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#What_Analysts_Are_Saying_About_Dr_Reddys_Laboratories_Q1_Results_FY27\" title=\"What Analysts Are Saying About Dr Reddys Laboratories Q1 Results FY27\">What Analysts Are Saying About Dr Reddys Laboratories Q1 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#Key_Watchpoints_for_Dr_Reddys_Laboratories\" title=\"Key Watchpoints for Dr Reddys Laboratories\">Key Watchpoints for Dr Reddys Laboratories<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#Revenue_Delivery_vs_Consensus_for_Dr_Reddys_Laboratories\" title=\"Revenue Delivery vs Consensus for Dr Reddys Laboratories\">Revenue Delivery vs Consensus for Dr Reddys Laboratories<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#PAT_Performance_in_Q1_Results_FY27\" title=\"PAT Performance in Q1 Results FY27\">PAT Performance in Q1 Results FY27<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#Risks_to_the_Dr_Reddys_Laboratories_Prediction\" title=\"Risks to the Dr Reddys Laboratories Prediction\">Risks to the Dr Reddys Laboratories Prediction<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#Below-Consensus_Revenue_Growth\" title=\"Below-Consensus Revenue Growth\">Below-Consensus Revenue Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#PAT_Pressure_in_Q1_Results_FY27\" title=\"PAT Pressure in Q1 Results FY27\">PAT Pressure in Q1 Results FY27<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#Conclusion_Dr_Reddys_Laboratories\" title=\"Conclusion: Dr Reddys Laboratories\">Conclusion: Dr Reddys Laboratories<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#Frequently_Asked_Questions_on_Dr_Reddys_Laboratories\" title=\"Frequently Asked Questions on Dr Reddys Laboratories\">Frequently Asked Questions on Dr Reddys Laboratories<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#What_is_Uniresearchs_PAT_prediction_for_Dr_Reddys_Laboratories_Q1_Results_FY27\" title=\"What is Uniresearch&#8217;s PAT prediction for Dr Reddys Laboratories Q1 Results FY27?\">What is Uniresearch&#8217;s PAT prediction for Dr Reddys Laboratories Q1 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#What_is_the_Revenue_prediction_for_Dr_Reddys_Laboratories_Q1_Results_FY27\" title=\"What is the Revenue prediction for Dr Reddys Laboratories Q1 Results FY27?\">What is the Revenue prediction for Dr Reddys Laboratories Q1 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#What_were_Dr_Reddys_Laboratories_Q1_Results_FY27\" title=\"What were Dr Reddys Laboratories Q1 Results FY27?\">What were Dr Reddys Laboratories Q1 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#Does_the_Dr_Reddys_Laboratories_Q1_Results_FY27\" title=\"Does the Dr Reddys Laboratories Q1 Results FY27?\">Does the Dr Reddys Laboratories Q1 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#What_is_the_analyst_target_price_mentioned_in_the_Dr_Reddys_Laboratories_Q1_Results_FY27\" title=\"What is the analyst target price mentioned in the Dr Reddys Laboratories Q1 Results FY27?\">What is the analyst target price mentioned in the Dr Reddys Laboratories Q1 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#What_are_the_risks_to_the_Dr_Reddys_Laboratories_Q1_Results_FY27\" title=\"What are the risks to the Dr Reddys Laboratories Q1 Results FY27?\">What are the risks to the Dr Reddys Laboratories Q1 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-q1-results-fy27\/#What_is_the_Q1_FY26_base_for_the_Dr_Reddys_Laboratories_Q1_Results_FY27\" title=\"What is the Q1 FY26 base for the Dr Reddys Laboratories Q1 Results FY27?\">What is the Q1 FY26 base for the Dr Reddys Laboratories Q1 Results FY27?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Reddys_Laboratories_Q1_Results_FY27_%E2%80%93_Uniresearch_Prediction\"><\/span><strong>Dr Reddys Laboratories Q1 Results FY27 &#8211; Uniresearch Prediction<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; font-size: 14px; margin: 16px 0;\">\n<tbody>\n<tr>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>Metric<\/strong><\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>Q1 FY26 Actual<\/strong><\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>Q1 Results FY27 Uniresearch Prediction<\/strong><\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>YoY Change<\/strong><\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>Source<\/strong><\/th>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\"><a href=\"https:\/\/univest.in\/stocks\/drreddy\/dr-reddy's-laboratories-ltd-share-price-today\">Dr Reddys Laboratories<\/a> Revenue (Rs Cr)<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">8,572<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">9,121<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">+6.4%<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Uniresearch | 39-analyst consensus applied to Q1 FY26 verified actual<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">PAT (Rs Cr)<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">1,410<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">1,449<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">+2.8%<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Uniresearch | 39-analyst consensus applied to Q1 FY26 verified actual<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Avg Analyst Target<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Rs 1,335<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">12-month view<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">&#8211;<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Analyst consensus (39 analysts)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"font-size: 12px; color: #666;\"><em>Predictions apply 39-analyst FY27 consensus (Rev +6.4%, PAT +2.8%) to Q1 FY26 verified actuals. Not guaranteed outcomes.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Reddys_Laboratories_Q4_FY26_Key_Metrics_%E2%80%93_Baseline_for_Dr_Reddys_Laboratories_Q1_Results_FY27\"><\/span><strong>Dr Reddys Laboratories Q4 FY26 Key Metrics &#8211; Baseline for Dr Reddys Laboratories Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; font-size: 14px; margin: 16px 0;\">\n<tbody>\n<tr>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>Metric<\/strong><\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>Q4 FY26 Actual<\/strong><\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>YoY Change<\/strong><\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>Source<\/strong><\/th>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Revenue (Rs Cr)<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">7,546<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">-11.5% YoY<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Consolidated quarterly financial data<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">PAT (Rs Cr)<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">221<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">-86.1% YoY<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Consolidated quarterly financial data<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"What_Analysts_Are_Saying_About_Dr_Reddys_Laboratories_Q1_Results_FY27\"><\/span><strong>What Analysts Are Saying About Dr Reddys Laboratories Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Across 39 analysts covering Dr Reddys Laboratories, the FY27 consensus projects revenue growth of +6.4% and profit growth of +2.8%, with an average 12-month price target of Rs 1,335. The Q1 Results FY27 prediction reflects this consensus applied to verified Q1 FY26 actuals.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Watchpoints_for_Dr_Reddys_Laboratories\"><\/span><strong>Key Watchpoints for Dr Reddys Laboratories<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_Delivery_vs_Consensus_for_Dr_Reddys_Laboratories\"><\/span><strong>Revenue Delivery vs Consensus for Dr Reddys Laboratories<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The primary watchpoint is whether Revenue in Q1 Results FY27 delivers in line with the Uniresearch projection of Rs 9,121 Cr (+6.4% consensus growth). Q1 FY26 base was Rs 8,572 Cr.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"PAT_Performance_in_Q1_Results_FY27\"><\/span><strong>PAT Performance in Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The PAT watchpoint is whether Dr Reddys Laboratories achieves Rs 1,449 Cr (+2.8% growth from Q1 FY26 base of Rs 1,410 Cr). Q4 FY26 PAT was Rs 221 Cr.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_the_Dr_Reddys_Laboratories_Prediction\"><\/span><strong>Risks to the Dr Reddys Laboratories Prediction<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Below-Consensus_Revenue_Growth\"><\/span><strong>Below-Consensus Revenue Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>If Revenue comes in below the +6.4% consensus, actual revenue would fall short of Rs 9,121 Cr.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"PAT_Pressure_in_Q1_Results_FY27\"><\/span><strong>PAT Pressure in Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The PAT prediction of Rs 1,449 Cr could be impacted by cost escalation not factored into the 39-analyst consensus of +2.8%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_Dr_Reddys_Laboratories\"><\/span><strong>Conclusion: Dr Reddys Laboratories<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Dr Reddys Laboratories Uniresearch prediction of Revenue Rs 9,121 Cr and PAT Rs 1,449 Cr is derived from the 39-analyst consensus FY27 growth rates applied to verified Q1 FY26 actuals. When Q1 Results FY27 are declared, investors can benchmark actual performance against this consensus prediction. Track live updates on Univest.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Track Dr Reddys Laboratories Live on the Univest Screener<\/strong><\/a><\/p>\n<p><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> for live Q1 Results FY27 alerts.<\/em><\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Revenue and PAT actuals are sourced from consolidated quarterly financial data. Q1 Results FY27 Uniresearch predictions are derived by applying analyst consensus growth rates to verified Q1 FY26 actuals &#8211; these are analyst consensus projections and are not guaranteed outcomes. Investments in securities are subject to market risk. For educational purposes only. SEBI RA INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Dr_Reddys_Laboratories\"><\/span><strong>Frequently Asked Questions on Dr Reddys Laboratories<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Uniresearchs_PAT_prediction_for_Dr_Reddys_Laboratories_Q1_Results_FY27\"><\/span><strong>What is Uniresearch&#8217;s PAT prediction for Dr Reddys Laboratories Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Uniresearch projects Dr Reddys Laboratories PAT at Rs 1,449 Cr, applying 39-analyst FY27 profit growth consensus of +2.8% to Q1 FY26 verified PAT of Rs 1,410 Cr.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Revenue_prediction_for_Dr_Reddys_Laboratories_Q1_Results_FY27\"><\/span><strong>What is the Revenue prediction for Dr Reddys Laboratories Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Reddys Laboratories Revenue is projected at Rs 9,121 Cr, applying +6.4% FY27 revenue consensus to verified Q1 FY26 base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Dr_Reddys_Laboratories_Q1_Results_FY27\"><\/span><strong>What were Dr Reddys Laboratories Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Q4 FY26 consolidated Revenue was Rs 7,546 Cr (-11.5% YoY) and PAT was Rs 221 Cr (-86.1% YoY).<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Does_the_Dr_Reddys_Laboratories_Q1_Results_FY27\"><\/span><strong>Does the Dr Reddys Laboratories Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. All predictions in this article are derived from the 39-analyst consensus applied to verified Q1 FY26 actuals.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_analyst_target_price_mentioned_in_the_Dr_Reddys_Laboratories_Q1_Results_FY27\"><\/span><strong>What is the analyst target price mentioned in the Dr Reddys Laboratories Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 39-analyst consensus gives an average 12-month price target of Rs 1,335 for Dr Reddys Laboratories.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_risks_to_the_Dr_Reddys_Laboratories_Q1_Results_FY27\"><\/span><strong>What are the risks to the Dr Reddys Laboratories Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Risks include below-consensus revenue growth (target: +6.4%) and unexpected cost pressures impacting the +2.8% PAT consensus.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Q1_FY26_base_for_the_Dr_Reddys_Laboratories_Q1_Results_FY27\"><\/span><strong>What is the Q1 FY26 base for the Dr Reddys Laboratories Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Q1 FY26 consolidated Revenue was Rs 8,572 Cr and PAT was Rs 1,410 Cr. These form the base for the Dr Reddys Laboratories prediction.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is Uniresearch's PAT prediction for Dr Reddys Laboratories Q1 Results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Uniresearch projects Dr Reddys Laboratories Q1 Results FY27 PAT at Rs 1,449 Cr, applying 39-analyst FY27 profit growth consensus of +2.8% to Q1 FY26 verified PAT of Rs 1,410 Cr.\"}},{\"@type\":\"Question\",\"name\":\"What is the Revenue prediction for Dr Reddys Laboratories Q1 Results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Reddys Laboratories Q1 Results FY27 Revenue is projected at Rs 9,121 Cr, applying +6.4% FY27 revenue consensus to verified Q1 FY26 base.\"}},{\"@type\":\"Question\",\"name\":\"What were Dr Reddys Laboratories Q1 Results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Q4 FY26 consolidated Revenue was Rs 7,546 Cr (-11.5% YoY) and PAT was Rs 221 Cr (-86.1% YoY).\"}},{\"@type\":\"Question\",\"name\":\"Does the Dr Reddys Laboratories Q1 Results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. All predictions in this article are derived from the 39-analyst consensus applied to verified Q1 FY26 actuals.\"}},{\"@type\":\"Question\",\"name\":\"What is the analyst target price mentioned in the Dr Reddys Laboratories Q1 Results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The 39-analyst consensus gives an average 12-month price target of Rs 1,335 for Dr Reddys Laboratories.\"}},{\"@type\":\"Question\",\"name\":\"What are the risks to the Dr Reddys Laboratories Q1 Results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Risks include below-consensus revenue growth (target: +6.4%) and unexpected cost pressures impacting the +2.8% PAT consensus.\"}},{\"@type\":\"Question\",\"name\":\"What is the Q1 FY26 base for the Dr Reddys Laboratories Q1 Results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Q1 FY26 consolidated Revenue was Rs 8,572 Cr and PAT was Rs 1,410 Cr. These form the base for the Dr Reddys Laboratories Q1 Results FY27 prediction.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr Reddys Laboratories Q1 Results FY27: Uniresearch projects Q1 Results FY27 Revenue Rs 9,121 Cr and PAT Rs 1,449 Cr (39-analyst consensus). Q4 FY26 actuals, analyst views and watchpoints inside.<\/p>\n","protected":false},"author":35,"featured_media":130701,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-130496","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1782367448:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["82"],"rank_math_focus_keyword":["Dr Reddys Laboratories Q1 Results FY27"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Dr Reddys Laboratories Q1 Results FY27: Uniresearch Predictions, Analyst Views and Key Watchpoints"],"rank_math_description":["Dr Reddys Laboratories Q1 Results FY27: Uniresearch projects Q1 Results FY27 Revenue Rs 9,121 Cr and PAT Rs 1,449 Cr (39-analyst consensus). Q4 FY26 actuals, analyst views and watchpoints inside."],"_thumbnail_id":["130701"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["21139"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Dr-Reddys-Laboratories-Q1-Results-FY27.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/130496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=130496"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/130496\/revisions"}],"predecessor-version":[{"id":130702,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/130496\/revisions\/130702"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/130701"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=130496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=130496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=130496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}